|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0018787,
umls-concept:C0035647,
umls-concept:C0205177,
umls-concept:C0205531,
umls-concept:C0226896,
umls-concept:C0231491,
umls-concept:C0392756,
umls-concept:C0441833,
umls-concept:C0442027,
umls-concept:C0813983,
umls-concept:C0935763,
umls-concept:C1332700,
umls-concept:C1515655,
umls-concept:C1527415,
umls-concept:C1875307,
umls-concept:C1880355,
umls-concept:C2354243
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-3-17
|
|
pubmed:abstractText |
Introduction of polar groups in a series of potent CCR5 antagonists which are very likely to adversely affect the conduction system in the heart led to the identification of NIBR-1282 which did not show adverse effects when tested in an isolated rabbit heart ex vivo model. Administration of NIBR-1282 in combination with a non-efficacious dose of CsA led to significant prolongation of kidney allograft survival in cynomolgus monkeys.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CCL3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CCL3,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/Ether-A-Go-Go Potassium Channels,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/KCNH1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR5
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2000-5
|
|
pubmed:meshHeading |
pubmed-meshheading:18267361-Administration, Oral,
pubmed-meshheading:18267361-Animals,
pubmed-meshheading:18267361-Biological Availability,
pubmed-meshheading:18267361-CHO Cells,
pubmed-meshheading:18267361-Caco-2 Cells,
pubmed-meshheading:18267361-Chemokine CCL3,
pubmed-meshheading:18267361-Cricetinae,
pubmed-meshheading:18267361-Cricetulus,
pubmed-meshheading:18267361-Cyclosporine,
pubmed-meshheading:18267361-Cytochrome P-450 Enzyme System,
pubmed-meshheading:18267361-Dogs,
pubmed-meshheading:18267361-Ether-A-Go-Go Potassium Channels,
pubmed-meshheading:18267361-Graft Survival,
pubmed-meshheading:18267361-Heart,
pubmed-meshheading:18267361-Humans,
pubmed-meshheading:18267361-Immunosuppressive Agents,
pubmed-meshheading:18267361-Kidney Transplantation,
pubmed-meshheading:18267361-Macaca fascicularis,
pubmed-meshheading:18267361-Pyridines,
pubmed-meshheading:18267361-Rabbits,
pubmed-meshheading:18267361-Radioligand Assay,
pubmed-meshheading:18267361-Rats,
pubmed-meshheading:18267361-Receptors, CCR5
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo.
|
|
pubmed:affiliation |
Novartis Institutes for BioMedical Research, Forum 1, Novartis Campus, CH-4002 Basel, Switzerland. gebhard.thoma@novartis.com
|
|
pubmed:publicationType |
Journal Article
|
